Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptatsh1654

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:30:14 ON 10 MAY 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:30:47 ON 10 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2008 HIGHEST RN 1020227-00-2
DICTIONARY FILE UPDATES: 9 MAY 2008 HIGHEST RN 1020227-00-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> PP.S.DL..H..RE.L....A.Q.A.QE...R...../SQSP
L1 19 PP.S.DL..H..RE.L....A.Q.A.QE...R...../SQSP

=> FIL HCAP

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.70	32.91

FILE 'HCAPLUS' ENTERED AT 12:33:32 ON 10 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

FILE COVERS 1907 - 10 May 2008 VOL 148 ISS 20
FILE LAST UPDATED: 9 May 2008 (20080509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> L1
L2 5 L1

=> D L2 1-5 IBIB ABS HITSTR

L2 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1480503 HCAPLUS
DOCUMENT NUMBER: 148:254116
TITLE: Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats
AUTHOR(S): Yuan, P.-Q.; Million, M.; Wu, S. V.; Rivier, J.; Tache, Y.
CORPORATE SOURCE: CURE: Digestive Diseases Research Center, and Center for Neurovisceral Sciences & Women's Health, VA Greater Los Angeles Healthcare System, Digestive Diseases Division, Department of Medicine and Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA
SOURCE: Neurogastroenterology & Motility (2007), 19(11), 923-936
CODEN: NMOTEK; ISSN: 1350-1925
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB I.p. (i.p.) corticotropin releasing factor (CRF) induced a CRF1 receptor-dependent stimulation of myenteric neurons and motility in the rat proximal colon. We characterize the colonic enteric nervous system response to CRF in conscious rats. Laser capture microdissection combined with reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochem. in longitudinal muscle myenteric plexus whole-mount colonic prepns. revealed CRF1 receptor expression in myenteric neurons. CRF (i.p., 10 μg kg-1) induced Fos immunoreactivity (IR) (cells per ganglion) selectively in myenteric plexus of proximal (18.3 ± 2.4 vs vehicle: 0.0 ± 0.0) and distal colon (16.8 ± 1.2 vs vehicle: 0.0 ± 0.0), but not in that of gastric corpus, antrum, duodenum, jejunum and ileum. The selective CRF1 agonist, stressin1-A (i.p., 10 μg kg-1)

also induced Fos IR in myenteric but not in submucosal plexus of the proximal and distal colon. Fos IR induced by CRF was located in 55 ± 1.9% and 53 ± 5.1% of CRF1 receptor-IR myenteric neurons and in 44 ± 2.8% and 40 ± 3.9% of cholinergic neurons with Dogiel type I morphol., and in 20 ± 1.6% and 80 ± 3.3% of nitrergic neurons in proximal and distal colon resp. CRF and stressin1-A elicit defecation and diarrhea. These data support that one mechanism through which peripherally injected CRF ligands stimulate colonic function involves a direct action on colonic cholinergic and nitrergic myenteric neurons expressing CRF1 receptor.

IT 935739-46-1, Stressin1 A
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(corticotropin releasing factor1 receptor agonist stressin1-A activated CRF1 expressing cholinergic, nitrergic myenteric neuron in colon eliciting defecation and diarrhea in rat)

RN 935739-46-1 HCAPLUS

CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-, (28→31)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L2 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1403262 HCAPLUS
DOCUMENT NUMBER: 148:70407
TITLE: Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats
AUTHOR(S): Zhao, Y.; Valdez, G. R.; Fekete, E. M.; Rivier, J. E.; Vale, W. W.; Rice, K. C.; Weiss, F.; Zorrilla, E. P.
CORPORATE SOURCE: Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 323(3), 846-854
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The corticotropin-releasing factor (CRF) system mediates stress responses. Extrahypothalamic CRF1 receptor activation has anxiogenic-like properties, but anxiety-related functions of CRF2 receptors remain unclear. The present study determined the effects of intracerebroventricular administration of a CRF2 agonist, urocortin 3, on behavior of male Wistar rats in the shock-probe, social interaction, and defensive withdrawal tests of anxiety-like behavior. Equimolar doses of stressin1-A, a novel CRF1 agonist, were administered to sep. rats. The effects of pyrazolo[1,5-a]-1,3,5-triazin-4-amine,8-[4-(bromo)-2-chlorophenyl]-N,N-bis(2-methoxyethyl)-2,7-dimethyl-(9CI) (MJL-1-109-2), a CRF1 antagonist, on behavior in the shock-probe test also were studied. Stressin1-A increased anxiety-like behavior in the social interaction and shock-probe tests. Stressin1-A elicited behavioral activation and defensive burying

at lower doses (0.04 nmol), but it increased freezing, grooming, and mounting at 25-fold higher (1-nmol) doses. Conversely, systemic administration of MJL-1-109-2 (10 mg/kg) had anxiolytic-like effects in the shock-probe test. Unlike stressin1-A or MJL-1-109-2, i.c.v. urocortin 3 infusion did not alter anxiety-like behavior in the shock-probe test across a range of doses that reduced locomotion and rearing and increased grooming. Urocortin 3 also did not decrease social interaction, but it decreased anxiety-like behavior in the defensive withdrawal test at a 2-nmol dose. Thus, i.c.v. administration of CRF1 and CRF2 agonists produced differential, but not opposite, effects on anxiety-like behavior. Urocortin 3 (i.c.v.) did not consistently decrease or increase anxiety-like behavior, the latter unlike effects seen previously after local microinjection of CRF2 agonists into the septum or raphe. With increasing CRF1 activation, however, the behavioral expression of anxiety qual. changes from "coping" to "noncoping" and offensive, agonistic behaviors.

IT 935739-46-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CRF subtype-selective contrasting, but not opposite, effects on anxiety-related behavior in rats)

RN 935739-46-1 HCAPLUS

CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-, (28→31)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1384929 HCAPLUS

DOCUMENT NUMBER: 148:230278

TITLE: Common and Divergent Structural Features of a Series of Corticotropin Releasing Factor-Related Peptides

AUTHOR(S): Grace, Christy Rani R.; Perrin, Marilyn H.; Cantle, Jeffrey P.; Vale, Wylie W.; Rivier, Jean E.; Riek, Roland

CORPORATE SOURCE: Structural Biology Laboratory and The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, CA, 92037, USA

SOURCE: Journal of the American Chemical Society (2007), 129(51), 16102-16114
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Members of the corticoliberin family include the corticotropin releasing factors (CRFs), sauvagine, the urotensins, and urocortin 1 (Ucn1), which bind to both the CRF receptors CRF-R1 and CRF-R2, and the urocortins 2 (Ucn2) and 3 (Ucn3), which are selective agonists of CRF-R2. Structure activity relationship studies led to several potent and long-acting

analogs with selective binding to either one of the receptors. NMR structures of six ligands of this family (the antagonists astressin B and astressin2-B, the agonists stressin1, and the natural ligands human Ucn1, Ucn2, and Ucn3) were determined in DMSO. These six peptides show differences in binding affinities, receptor-selectivity, and NMR structure. Overall, their backbones are α-helical, with a small kink or a turn around residues 25-27, resulting in a helix-loop-helix motif. The C-terminal helixes are of amphipathic nature, whereas the N-terminal helixes vary in their amphipathicity. The C-terminal helixes thereby assume a conformation very similar to that of astressin bound to the ECD1 of CRF-R2 recently reported by the authors' group. On the basis of an anal. of the observed 3D structures and relative potencies of [Ala]-substituted analogs, it is proposed that both helixes could play a crucial role in receptor binding and selectivity. In conclusion, the C-terminal helixes may interact along their hydrophobic faces with the ECD1, whereas the entire N-terminal helical surface may be involved in receptor activation. On the basis of the common and divergent features observed in the 3D structures of these ligands, multiple binding models are proposed that may explain their plurality of actions.

IT 1000906-76-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(common and divergent structural features of series of corticotropin releasing factor-related peptides)

RN 1000906-76-2 HCAPLUS

CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-isoleucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-, (28→31)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:247482 HCAPLUS

DOCUMENT NUMBER: 146:474752

TITLE: Stressin1-A, a Potent Corticotropin Releasing Factor Receptor 1 (CRF1)-Selective Peptide Agonist

AUTHOR(S): Rivier, Jean; Gulyas, Jozsef; Kunitake, Koichi; DiGruccio, Michael; Cantle, Jeffrey P.; Perrin, Marilyn H.; Donaldson, Cindy; Vaughan, Joan; Million, Mulugeta; Gourcerol, Guillaume; Adelson, David W.; Rivier, Catherine; Tache, Yvette; Vale, Wylie

CORPORATE SOURCE: The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, CA, 92037, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(7), 1668-1674
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The potencies and selectivity of peptide CRF antagonists is increased through structural constraints, suggesting that the resulting ligands assume distinct conformations when interacting with CRF1 and CRF2 receptors. To develop selective CRF receptor agonists, we have scanned the sequence -Gln-Ala-His-Ser-Asn-Arg- (residues 30-35 of [DPhe12,Nle21,38]Ac-hCRF4-41) with an i-(i+3) bridge consisting of the Glui-Xaa-Xbb-Lysi+3 scaffold, where residues i = 30, 31, and 32. When i = 31, stressin1-A, a potent CRF1 receptor-selective agonist was generated. In vitro, stressin1-A was equipotent to h/rCRF to release ACTH. Astressin1-A showed a low nanomolar affinity for CRF1 receptor (Ki = 1.7 nM) and greater than 100-fold selectivity vs. CRF2 receptor (Ki = 222 nM). Stressin1-A released slightly less ACTH than oCRF in adult adrenal-intact male rats, with increased duration of action. Stressin1-A, injected i.p. in rats, induced fecal pellet output (a CRF1 receptor-mediated response) and did not influence gastric emptying and blood pressure (CRF2 receptor-mediated responses).

IT 935739-45-0P 935739-46-1P, Stressin1-A
935739-47-2P 935739-49-4P 935739-51-8P
935739-53-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Stressin1-A as CRF1-selective peptide agonist)

RN 935739-45-0 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 935739-46-1 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-, (28→31)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 935739-47-2 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-N-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-N-methyl-L-leucyl- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 935739-49-4 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-

L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-N-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-N-methyl-L-leucyl-, (28→31)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 935739-51-8 HCAPLUS
CN L-Alaninamide, L-seryl-L-glutaminyl-L-α-glutamyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-threonyl-L-lysyl-L-alanyl-L-α-aspartyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-α-aspartyl-L-isoleucyl-, (31→34)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 935739-53-0 HCAPLUS
CN L-Alaninamide, L-seryl-L-glutaminyl-L-α-glutamyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-threonyl-L-lysyl-L-alanyl-L-α-aspartyl-L-glutaminyl-N-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-α-aspartyl-L-isoleucyl-, (31→34)-lactam (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:117793 HCAPLUS
DOCUMENT NUMBER: 138:153832
TITLE: Preparation of corticotropin-releasing factor (CRF) analogs as CRF receptor type 1 (CRFR1) selective ligands
INVENTOR(S): Rivier, Jean E. F.; Vale, Wylie W., Jr.; Perrin, Marilyn H.; Guylas, Jozsef
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011823	A2	20030213	WO 2002-US24238	20020730
WO 2003011823	A3	20070920		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, OA

CA 2455223	A1	20030213	CA 2002-2455223		20020730
AU 2002355742	A1	20030217	AU 2002-355742		20020730
JP 2005510458	T	20050421	JP 2003-517015		20020730
EP 1572679	A2	20050914	EP 2002-752639		20020730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
US 20040204564	A1	20041014	US 2004-763935		20040122
PRIORITY APPLN. INFO.:			US 2001-309504P	P	20010801
			WO 2002-US24238	W	20020730

OTHER SOURCE(S): MARPAT 138:153832

AB Corticotropin-releasing factor (CRF) peptides Y1-Pro-Pro-R6-Ser-R8-Asp-R10-R11-D-Phe-R13-R14-R15-Arg-R17-R18-R19-R20-R21-R22-R23-R24-R25-R26-R27-R28-R29-Gln-Glu-R32-R33-R34-Arg-R36-R37-R38-R39-R40-R41-NH2 (Y1 is acyl having < 15 carbon atoms or radioiodinated tyrosine; the R groups represent various amino acid residues which are defined) or their nontoxic salts are claimed for selective binding to CRFR1. Thus, cyclo(31-34)(Ac-Pro4,D-Phe12,Nle21,38,Glu31,Lys34)-r/hCRF(4-41) was prepared by the solid-phase method and shown to bind hCRFR1 with high affinity and significantly lowered blood pressure when administered peripherally.

IT 496031-18-6P 496031-20-0P 496031-22-2P
496031-24-4P 496031-25-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of corticotropin-releasing factor (CRF) analogs as CRF receptor type 1 (CRFR1) selective ligands)

RN 496031-18-6 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 496031-20-0 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-2-methylalanyl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 496031-22-2 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-

methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-D-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-24-4 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-D-alanyl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-25-5 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 496031-14-2P 496031-15-3P 496031-16-4P
496031-17-5P 496031-19-7P 496031-21-1P
496031-23-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of corticotropin-releasing factor (CRF) analogs as CRF receptor type 1 (CRFR1) selective ligands)
RN 496031-14-2 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-15-3 HCAPLUS
CN L-Leucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-2-methyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-16-4 HCAPLUS
CN L-Leucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-

α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-2-methylalanyl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-L-isoleucyl-2-methyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-17-5 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-L-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-19-7 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-2-methylalanyl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-21-1 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-D-seryl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 496031-23-3 HCAPLUS
CN L-Isoleucinamide, 1-acetyl-L-prolyl-L-prolyl-L-isoleucyl-L-seryl-L-leucyl-L-α-aspartyl-L-leucyl-L-threonyl-D-phenylalanyl-L-histidyl-L-leucyl-L-leucyl-L-arginyl-L-α-glutamyl-L-valyl-L-leucyl-L-α-glutamyl-L-norleucyl-L-alanyl-L-arginyl-L-alanyl-L-α-glutamyl-L-glutaminyl-2-methyl-L-leucyl-L-alanyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-histidyl-D-alanyl-L-lysyl-L-arginyl-L-lysyl-L-leucyl-L-norleucyl-L-α-glutamyl-2-methyl-L-leucyl-, (28→31)-lactam (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> D QUE STAT
L1 19 SEA FILE=REGISTRY ABB=ON PLU=ON PP.S.DL..H..RE.L....A.Q.A.QE...R...../SQSP
L2 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L1

```
=> D HIS FULL

     (FILE 'HOME' ENTERED AT 12:30:14 ON 10 MAY 2008)

     FILE 'REGISTRY' ENTERED AT 12:30:47 ON 10 MAY 2008
L1           19 SEA ABB=ON  PLU=ON  PP.S.DL..H..RE.L....A.Q.A.QE...R...../SQSP


     FILE 'HCAPLUS' ENTERED AT 12:33:32 ON 10 MAY 2008
L2            5 SEA ABB=ON  PLU=ON  L1
                D L2 1-5 IBIB ABS HITSTR
                D QUE STAT


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    9 MAY 2008  HIGHEST RN 1020227-00-2
     DICTIONARY FILE UPDATES:   9 MAY 2008  HIGHEST RN 1020227-00-2

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/support/stngen/stndoc/properties.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 10 May 2008  VOL 148 ISS 20
     FILE LAST UPDATED: 9 May 2008  (20080509/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.